How many joys and how many sorrows? ESMO three major lung cancer new drug data released

*For medical professionals only

More treatment options for NSCLC

• For the primary endpoint DFS, there was no significant improvement in the CAN group compared to the PBO group (median 35.
  
  (There was no significant difference between the primary endpoints of Figure 2 between DFS groups.
  
  (There was no significant difference in DFS between subgroup analysis groups in Figure 3.
  
  (Figure 4 Comparison of the two sets of AEs)
  
  • No new security issues were found for
    the CAN group.
    
    (Figure 5 Most Common Adverse Events) CEMI's First 3-Year Survival Data Disease Progression Treatment Still Improves ▌ 3-Year Survival Rate
    in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    After Receiving CEMI Chemotherapy Summary No.
    
    
    • The median OS was 23.
      
      (Figure 7 Comparison of OS and PFS data from three-year follow-up of random groups)
      
      • At 3-year follow-up, in 50% of patients ≥ PD-L1, CEMI-treated patients had significantly longer
        OS compared to chemotherapy.
        
        (Figure 8 In 50% of patients ≥ PD-L1, the OS of CEMI-treated patients was significantly prolonged.
        
        (Figure 9 In 50% of patients ≥ PD-L1, the FPS of CEMI-treated patients was significantly prolonged.
        
        (Figure 10 CEMI induced higher ORR and longer duration of response)
        ■ Follow-up treatment of disease progression 64 patients continued to receive CEMI+ chemotherapy as a follow-up treatment
        
        .
        
        
        
        
        • The DOR, PFS and OS of patients in the M1500+C group were higher than those in the P+C group
          .
          
          (Figure 14 Intergroup DOR, PDS and OS comparison)
          
          • Efficacy data analysis showed that the ORR was 40.
            
            (Figure 15 MEDI5752+CTx has a significant effect)
            
            • Consistent with the pharmacodynamic effects of CTLA-4 blockade, M1500+C and M750+C lead to more significant
              proliferation of T cells than P+C.
              
              (Figure 16 Comparison of T cell growth between two groups)
              
              • The efficacy of M750+C was significantly improved, especially in the PD-L1<1% subgroup, and the tolerance was improved<b10>.
                
                
              
              
              (Fig.
              17 In the PD-L1 <1% subgroup, patients were better tolerated.
              )